非奈利酮不同版本一盒的最新价格公布

Introduction: Fenelidone is a drug used to treat diabetic nephropathy and chronic kidney disease. In recent years, it has received widespread attention due to its remarkable efficacy. With the introduction of different versions of the drug, patients have more choices when choosing their medication.

The latest prices for a box of different versions of Fenelidone are announced

The prices vary depending on the version, specification and purchase channel. The following will analyze the prices of original drugs, generic drugs and the reasons for price differences.

Original drug price

The original drug of Fenelidone was developed by the German company Bayer and its trade name is "Keshenda". The original drug of fenelidone has been launched in China and has been included in medical insurance. The winning price of medical insurance is about US$28. The price after reimbursement will be lower and needs to be calculated according to the reimbursement ratio of each region.

The version of fenelidone exported to Japan by Germany's Bayer is 10mg*100 tablets per box, and the price per box is approximately US$180.

Generic drug prices

With the end of the patent period of fenelinone, many domestic pharmaceutical companies have begun to produce generic drugs. The price of generic drugs is usually lower. The generic version of Fenelidone produced by Lucius in Laos is a box of 10mg*30 tablets, and the price of a box is about US$19.

Reasons for price differences

The price difference between original drugs and generic drugs is mainly due to factors such as research and development costs, production processes, and market positioning. Original drugs invest a lot of money and time in the research and development process, while generic drugs achieve price advantages by simplifying the production process and reducing research and development costs.

Understanding the latest prices of different versions of fenelidone can help patients make reasonable choices based on their financial situation and medication needs.

The domestic marketing situation of Fenelidone

The domestic marketing situation of Fenelidone is relatively complicated, involving multiple brands of original drugs and generic drugs.

Marketing Status of Original Drugs

The original drug "Keshenda" of Fenelidone was approved for marketing in China in 2021, becoming the first domestic Fenelidone drug for the treatment of diabetic nephropathy. The launch of original drugs provides new treatment options for domestic patients, but its higher price also limits the use of some patients.

Generic drug marketing situation

With the end of the patent period of fenelidone, many domestic pharmaceutical companies have begun to produce generic drugs. Currently, there are many brands of nonelidone generics on the domestic market, such as Hengrui Medicine’s “finelidone” and Zhengda Tianqing’s “linelidone”. The launch of generic drugs provides patients with more choices and intensifies market competition.

The medical insurance reimbursement situation of fenelidone

The medical insurance reimbursement situation of fenelidone varies according to different regions and medical insurance policies.

Inclusion status in the medical insurance catalog

Fenelidone has been included in the national medical insurance catalog, and patients can reimburse part of the cost through medical insurance. After being included in the medical insurance catalog, the price of fenelidone has dropped, reducing the financial burden on patients.

Reimbursement ratio

The medical insurance reimbursement ratio of fenelidone varies depending on the region and type of medical insurance. It is recommended to consult the hospital or the medical insurance department for clarification.

Reimbursement conditions

The medical insurance reimbursement of fenelidone usually needs to meet certain conditions, such as patients need to provide relevant diagnosis certificates and prescriptions. In addition, some areas also have certain restrictions on the dosage and course of treatment of fenelidone, and patients need to use the medication rationally under the guidance of a doctor.

Understanding the medical insurance reimbursement status of fenelidone can help patients better plan their medication costs and reduce their financial burden.